- New Data from MAVORIC Trial Sheds Light on Key Characteristics of Long-term POTELIGEO® (mogamulizumab-kpkc) Responders with Specific Subtypes of Cutaneous T-cell Lymphoma
- Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
- Kyowa Kirin North America Announces Recipients of Patient Education Grants to Address Disparities for African-American Patients with Cutaneous T-Cell Lymphomas (CTCL)
Kyowa Kirin Co Ltd (4151:TYO) closed at 2,818.00, -7.91% below its 52-week high of 3,060.00, set on Sep 30, 2020.
1,849.00Mar 19 20203,060.00Sep 30 2020
Markit short selling activity
|Market cap||1.52tn JPY|
|EPS (TTM)||89.78 |
|Annual div (ADY)||44.00 |
|Annual div yield (ADY)||1.56%|
|Div ex-date||Dec 29 2020|
Data delayed at least 20 minutes, as of Jan 15 2021 06:00 GMT.